Form 4: Regeneron Director Bonnie L. Bassler Executes Stock Option and Sells Shares

Director Bonnie L. Bassler exercised stock options and sold shares of Regeneron Pharmaceuticals, Inc. on August 15, 2024, according to a Form 4 filing.

Summary

• On August 15, 2024, Bonnie L. Bassler, a director of Regeneron Pharmaceuticals, Inc., executed a transaction involving the company's stock.
• Bassler exercised non-qualified stock options to acquire 756 shares of common stock at a price of $371.4 per share.
• Simultaneously, Bassler sold 756 shares of common stock at a price of $1,170.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 27, 2024.
• Following these transactions, Bassler directly owns 1,382 shares of Regeneron common stock and holds options for 1,516 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were pre-planned under a 10b5-1 plan and do not necessarily indicate a change in the director's outlook on the company.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, transactions under 10b5-1 plans are pre-arranged and may not reflect current sentiment.

Comparison to Industry Standards

• Comparing Bassler's transactions to other pharmaceutical company directors' dealings requires analyzing similar Form 4 filings.
• Generally, stock option exercises and sales are common among executives and directors, often used for personal financial planning.
• The significance of these transactions depends on the size relative to Bassler's total holdings and the context of Regeneron's performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates